Cargando…

Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients

Detalles Bibliográficos
Autores principales:	Beechinor, R., Palumbo, A., Chew, H.K., Arora, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897179/ https://www.ncbi.nlm.nih.gov/pubmed/35131650 http://dx.doi.org/10.1016/j.esmoop.2022.100393

Ejemplares similares

Erratum to ‘Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients’: [ESMO Open Volume 7, Issue 1, February 2022, 100393]
por: Beechinor, R., et al.
Publicado: (2022)

Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2022)

Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer
por: Altundag, Kadri
Publicado: (2022)

Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
por: Del Re, M., et al.
Publicado: (2021)

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
por: Eser, Kadir, et al.
Publicado: (2022)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
por: Odabas, Hatice, et al.
Publicado: (2023)

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer
por: Lee, Ju-Eun, et al.
Publicado: (2023)

In reply: Personal protective equipment penetration performance may be affected by temperature and humidity
por: Wild, Evan, et al.
Publicado: (2021)

Reply to ‘Comment on “Tumour-agnostic drugs in paediatric cancers”’
por: Chisholm, Julia C., et al.
Publicado: (2020)

Pausing drugs and spacing vaccines: an open question – Authors' reply
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Reply to Editorial, May, 1898
por: Brown, G. Carleton
Publicado: (1898)

Palbociclib in metastatic breast cancer: current evidence and real-life data
por: Serra, Francesco, et al.
Publicado: (2019)

Educating Health Professionals about Drug and Device Promotion: Authors' Reply
por: Mansfield, Peter R, et al.
Publicado: (2007)

Reply to Chopra and Rizvi
por: Gandra, Sumanth, et al.
Publicado: (2019)

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
por: Leenhardt, Fanny, et al.
Publicado: (2022)

Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
por: Del Re, Marzia, et al.
Publicado: (2022)

Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design
por: Porcher, Raphaël, et al.
Publicado: (2022)

Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
por: Wedemeyer, Ralph-Steven, et al.
Publicado: (2014)

Effects of gastroesophageal reflux disease treatment with proton pump inhibitors on the risk of acute exacerbation and pneumonia in patients with COPD
por: Kang, Jieun, et al.
Publicado: (2023)

Reply to Comment on “UGT2B17 modifies drug response in chronic lymphocytic leukaemia”
por: Guillemette, Chantal, et al.
Publicado: (2020)

Reply to Borrelli et al.: Novel Drug Targets for Central Apneas in Heart Failure: On the Road
por: Orr, Jeremy E., et al.
Publicado: (2021)

Profile of palbociclib in the treatment of metastatic breast cancer
por: Ehab, Moataz, et al.
Publicado: (2016)

Proton pump inhibitors affect the gut microbiome
por: Imhann, Floris, et al.
Publicado: (2016)

Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2020)

Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
por: Raoul, J.L., et al.
Publicado: (2023)

Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug
por: Jain, Nirmal Kumar
Publicado: (2022)

Authors' Reply to “Translating palbociclib to the clinic for DIPG - What is truly achievable?”
por: Sun, Yu, et al.
Publicado: (2019)

COVID-19 Mortality: The Culprit May Not Be Proton Pump Inhibitors
por: Duan, Zhihui, et al.
Publicado: (2022)

Trough concentration may not be a good target for polymyxin B therapeutic drug monitoring
por: Zhao, Yuhua, et al.
Publicado: (2023)

Treatments for COVID-19: emerging drugs against the coronavirus - reply
por: Potì, Francesco
Publicado: (2020)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Pancytopenia Due to Possible Drug–Drug Interactions Between Low-Dose Methotrexate and Proton Pump Inhibitors
por: Tao, Dan, et al.
Publicado: (2022)

Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors
por: Gerson, Lauren B, et al.
Publicado: (2008)

An electronic proton-trapping ion pump for selective drug delivery
por: Strakosas, X., et al.
Publicado: (2021)

Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions.
por: Meyer, U. A.
Publicado: (1996)

Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy
por: Ikemura, Kenji, et al.
Publicado: (2017)

Proton-pump inhibitors among adults: a nationwide drug-utilization study
por: Hálfdánarson, Óskar Ö., et al.
Publicado: (2018)

Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors
por: Aggarwal, Nitish
Publicado: (2016)

Association of Proton Pump Inhibitor Use With Risk of Acquiring Drug-Resistant Enterobacterales
por: Willems, Roel P. J., et al.
Publicado: (2023)

Reply
por: Abdelrahman, Tamer, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sq87pgir0ickdld7243qntdv05